Biogen expands ophthalmology portfolio with $310m biosimilar deal
Biogen strikes deal with Samsung Bioepis for the commercial rights to two biosimilars referencing Lucentis and Eylea.
Archives for November 7, 2019
Vertex ramps up spending to support gene therapy manufacturing
Vertex Pharmaceuticals’ move into genetic therapies triggers a planned escalation of its manufacturing and research spending.